XML 91 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting - Summary of Segment Reporting Information (Detail)
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
CNY (¥)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
CNY (¥)
Dec. 31, 2022
CNY (¥)
Revenues:        
Revenues from services ¥ 290,738 $ 39,831 ¥ 345,030 ¥ 391,548
Revenues from sales of products 225,084 30,836 192,405 171,690
Total revenues 515,822 70,667 537,435 563,238
Cost of revenues: (153,422) (21,020) (174,208) (183,199)
Gross profit 362,400 49,647 363,227 380,039
Central laboratory business [Member]        
Revenues:        
Revenues from services 175,649 24,064 232,812 314,770
Revenues from sales of products 0 0 0 0
Total revenues 175,649 24,064 232,812 314,770
Cost of revenues: (33,808) (4,632) (49,473) (82,123)
Gross profit 141,841 19,432 183,339 232,647
In-hospital business [Member]        
Revenues:        
Revenues from services (592) (81) (3,704) 3,606
Revenues from sales of products 225,084 30,836 192,405 171,690
Total revenues 224,492 30,755 188,701 175,296
Cost of revenues: (65,099) (8,919) (72,570) (63,296)
Gross profit 159,393 21,836 116,131 112,000
Pharma research and development services [Member]        
Revenues:        
Revenues from services 115,681 15,848 115,922 73,172
Revenues from sales of products 0 0 0 0
Total revenues 115,681 15,848 115,922 73,172
Cost of revenues: (54,515) (7,469) (52,165) (37,780)
Gross profit ¥ 61,166 $ 8,379 ¥ 63,757 ¥ 35,392